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Edited by Lukas HuberAbstract Many studies have indicated that diﬀerentiated cells
inhibit drug-induced cytotoxicity but undiﬀerentiated cells do
not, though the mechanisms are unclear. Currently, HL-60 cells
are induced to diﬀerentiate into macrophage-like cells with Phor-
bol-12-myristate-13-acetate (TPA) treatment (TPA-diﬀerenti-
ated cells). Our study shows that caspase-9/-3-mediated
cytotoxicity can be induced in undiﬀerentiated HL-60 cells but
not in TPA-diﬀerentiated HL-60 cells. However, caspase-9/-3-
mediated cytotoxicity can be induced in TPA-diﬀerentiated cells
if they are pretreated with a protein kinase C (PKC) or a mito-
gen activated protein kinase (MEK) inhibitor. Taken together,
this study demonstrates that TPA-diﬀerentiated HL-60 cells in-
hibit caspases-9/-3-mediated cytotoxicity through the PKC and
MEK signaling pathways.
 2008 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
Keywords: Caspases; PKC; MEK; Diﬀerentiation1. Introduction
RC-RNase belongs to RNase A superfamilies, having
RNase activities and is derived from oocytes of bull frog
[1,2]. RC-RNase, a 13 kD protein, has a lectin domain
which may be associated to tumoricidal eﬀect [2,3]. Many
studies demonstrated that RC-RNase has anti-tumor eﬀects
[1–3] and RC-RNase-induced cytotoxicity was shown to cor-
relate with cell diﬀerentiation [4,5]. A study conducted by
Hu et al. showed that RC-RNase exerted a strong tumorici-
dal activity on poorly diﬀerentiated hepatoma cells com-
pared to a lower activity on well-diﬀerentiated hepatoma
cells [4]. A similar study also showed that RC-RNase-in-*Corresponding author. Fax: +886 4 26338212.
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doi:10.1016/j.febslet.2008.02.018duced cytotoxicity and caspase-9/-3 activities on HL-60 cells
but not on retinoic acid (RA)-diﬀerentiated-HL-60 cells [5].
This study aims to further test whether RC-RNase-induced
caspase-9/-3-mediated cytotoxicity is inhibited on TPA-diﬀer-
entiated cells.
The HL-60 cell line is a good system for studying diﬀerenti-
ation. HL-60 cells can be induced to diﬀerentiate into granulo-
cytes or macrophage-like cells following pretreatment with
diﬀerent factors, i.e., TPA pretreatment [6,7]. TPA is a diﬀer-
entiating agent that induced HL-60 cells to diﬀerentiate into
macrophage-like cells (TPA-diﬀerentiated cells) [8,9]. To
determine whether TPA-diﬀerentiated HL-60 cells inhibit
RC-RNase-induced cytotoxicity, HL-60 cells and TPA-diﬀer-
entiated HL-60 cells are treated with RC-RNase. Data from
our study showed that RC-RNase induces caspase-9/-3 activa-
tion and cytotoxicity on HL-60 cells, but not on TPA-diﬀeren-
tiated HL-60 cells. Many studies also showed that TPA can
induce HL-60 cells to diﬀerentiate into macrophage-like cells
through protein kinase C (PKC) and mitogen activated protein
kinase (MEK) pathways [10–12]. To examine whether PKC
and MEK pathways inhibit RC-RNase-induced cytotoxicity,
PKC inhibitor and MEK inhibitor are used in this study.
Our data showed that RC-RNase cannot directly induce cyto-
toxicity on TPA-diﬀerentiated HL-60 cells. However, RC-
RNase can induce cytotoxicity on TPA-diﬀerentiated HL-60
cells when it is pretreated with bisindolylmaleimide I or
PD98059. This study then indicates that RC-RNase-induced
cytotoxicity is inhibited on HL-60 cells through PKC and
MEK pathways.
Previous studies demonstrated that the MEK pathway
could inhibit caspase-8-mediated cell death [13,14]. However,
whether the MEK pathway can inhibit caspase-9 activation is
still unclear. In this study, RC-RNase induces caspase-9/-3
activation on HL-60 cells while RC-RNase cannot induce
caspase-9/-3 activation on TPA-diﬀerentiated HL-60 cells.
Furthermore, RC-RNase can only induce caspase-9/-3 activa-
tion on TPA-diﬀerentiated HL-60 cells after pretreatment
with bisindolylmaleimide I or PD98059. This data suggests
that the PKC or the MEK pathway can inhibit caspase-
9/-3 activation. Overall, this study demonstrates thatblished by Elsevier B.V. All rights reserved.
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caspases-9/-3 activation and cytotoxicity through the PKC
and the MEK pathways.Fig. 1. TPA induces HL-60 cells diﬀerentiation through PKC and
MEK pathways. (A) Undiﬀerentiated HL-60 cells are suspension cells
and are washed out before crystal violet staining. Thus, no cells are
stained on the dish. (B) TPA-diﬀerentiated HL-60 cells are attached
cells and can be stained with crystal violet on the dish. (C) HL-60 cells
are stained with crystal violet and the O.D. was determined at O.D.
550 nm in adhesion assay. Note that the O.D. value shows that only
TPA-diﬀerentiated cells (TPA) can adhere on the dish, but undiﬀer-
entiated (C), PD98059 (PD) and bisindolylmaleimide I (BI) pretreated
cells can not adhere on the dish. Each data point was calculated from
four triplicate groups and displayed as means ± S.D.2. Materials and methods
2.1. Chemicals and cell culture
TPA, RA and nitroblue tetrazolium (NBT) were purchased from
Sigma. DMSO was provided by Merck. Bisindolylmaleimide I and
PD98059 were obtained from Calbiochem. Ac-DEVD-pNA (caspase-
3 substrate) and Ac-LEHD-pNA (caspase-9 substrate) were procured
from Anaspec. HL-60 cells were cultured in RPMI1640 medium, sup-
plemented with 10% FBS, 2 mM L-glutamine, 100 IU/ml penicillin/
streptomycin, 1 mM sodium pyruvate, and 0.1 mM non-essential ami-
no acids (Gibco).
2.2. Puriﬁcation
RC-RNase could be puriﬁed [1,2]. Brieﬂy, RC-RNase was extracted
from yolk granules. The extract was centrifuged and the soluble frac-
tion was dissolved in PC buﬀer (20 mM HEPES, pH 7.9, 0.1 mM
EDTA). The supernatant was loaded onto a phosphocellulose column,
and the fractions containing RC-RNase were identiﬁed by CpG cleav-
age assay [1] and Ribonuclease activity assay [15]. These active frac-
tions were collected and loaded onto a carboxymethyl cellulose
column. The fractions containing RC-RNase activity were analyzed
by SDS–PAGE. The purity of RC-RNase was determined by the Brad-
ford method [16].
2.3. Diﬀerentiation and adhesion assay
A solution containing 100 ll of 5 · 104/ml cells was seeded on a 96-
well dish and treated with 20 nM TPA for 1 day (TPA was dissolved in
DMSO, ﬁnal concentration of DMSO in media was less than 0.02%).
Control cells were treated with a similar concentration of DMSO. To
examine the role of PKC and MEK pathways, 2 lM PKC inhibitor,
bisindolylmaleimide I and 25 lM MEK inhibitor, PD98059, were
added to the media, respectively, 30 min prior to the addition of
TPA. The numbers of TPA-diﬀerentiated cells were determined using
an adhesion assay [11]. Brieﬂy, cells were ﬁxed with 10% formalin
for 10 min and incubated at 37 C for 30 min after addition of 0.5%
crystal violet (in 20% methanol) and subsequently washed. After wash-
ing, the stain was eluted with 0.1 M sodium citrate (pH 4.2, in 50% eth-
anol) and was measured at 550 nm in an ELISA reader (Molecular
Devices).
2.4. RA-diﬀerentiated cells and NBT assay
HL-60 cells were induced to diﬀerentiate into granulocytes (RA-dif-
ferentiated cells) by treating with 1 lM RA for 5 days. The number of
RA-diﬀerentiated cells were determined by NBT assay [5]. Brieﬂy, HL-
60 cells were incubated at 37 C for 40 min after addition of 0.2% NBT
containing 200 ng/ml TPA. Intracellular blue formazan deposits could
be detected in diﬀerentiated cells. A minimum of 200 cells were
counted.
2.5. Cell proliferation assay
Approximately, 105/ml cells (containing HL-60 cells and TPA-diﬀer-
entiated cells, HL-60 cells pretreated with PD98059, HL-60 cells pre-
treated with bisindolylmaleimide I, TPA-diﬀerentiated cells
pretreated with PD98059 and TPA-diﬀerentiated cells pretreated with
bisindolylmaleimide I) were treated with 20 lg/ml RC-RNase. Cell
proliferation was determined daily using a hemocytometer with trypto-
phan blue stain.
2.6. Caspase activity assay
Cell lysates were obtained by treating cells with a lysis buﬀer (50 mM
Tris–HCl; 120 mM NaCl; 1 mM EDTA; 1% NP-40, pH 7.5) supple-
mented with protease inhibitors (Calbiochem). Caspase assay were
performed by pipetting 40 ll cell lysates to a 96-well dish, contain-
ing 158 ll reaction buﬀer (20% glycerol; 0.5 mM EDTA; and
5 mM DTT; 100 mM Hepes, pH 7.5), and 2 ll ﬂuorogenic
Ac-DEVD-pNA or Ac-LEHD-pNA. Samples were incubated for 8 h
at 37 C and determined at 405 nm in an ELISA reader (MolecularDevices). The increasing fold of caspase activity was indicated as
A405(RC-RNase treatment)/A405(control: withoutRC-RNase treatment). This meth-
od has been described previously [3,5,17].3. Results
3.1. Successful induction of diﬀerentiation on HL-60 cells with
TPA treatment
After TPA treatment for 1 day, undiﬀerentiated HL-60 cells
were induced to diﬀerentiate into macrophage-like cells (TPA-
diﬀerentiated cells). Undiﬀerentiated cells and TPA-diﬀerenti-
ated cells could be easily determined by an adhesion assay.
Undiﬀerentiated (suspension) cells were washed out prior to
adhesion assay. Thus, no cells were stained (Fig. 1A). An
O.D. value close to 0 was observed in the adhesion assay
(Fig. 1C). TPA-diﬀerentiated (attached) cells are stained with
crystal violet (Fig. 1B). Here, an O.D. value of nearly 2 was ob-
served (Fig. 1C). To test the role of the PKC and MEK path-
way, a PKC inhibitor (bisindolylmaleimide I) and a MEK
inhibitor (PD98059) were used to pretreat the cells. Again,
an O.D. value close to 0 was observed in the adhesion assay
(Fig. 1C). Hence, the data indicate that TPA induces HL-60
cells diﬀerentiation through the PKC and MEK pathways.
3.2. TPA-diﬀerentiated cells inhibit RC-RNase-induced
cytotoxicity
As shown in Fig. 2A, RC-RNase induces cytotoxicity which
leads to a decrease in the number of undiﬀerentiated cells.
Though growth arrest was found in TPA-diﬀerentiated cells,
there was no signiﬁcant diﬀerence in cell number between
TPA-diﬀerentiated cells without RC-RNase treatment and
those with RC-RNase treatment (Fig. 3A). Thus, TPA-diﬀer-
entiated cells inhibit RC-RNase-induced cytotoxicity while
undiﬀerentiated cells do not. Additionally, bisindolylmaleim-
ide I and PD98059 were used to test whether MEK and
PKC pathways could inhibit RC-RNase-induced cytotoxicity.
Our data show that RC-RNase does not decrease the cell num-
Fig. 2. RC-RNase induces cytotoxicity on undiﬀerentiated cells. (A) RC-RNase induces cytotoxicity on undiﬀerentiated HL-60 cells. (B) RC-RNase
induces cytotoxicity on undiﬀerentiated HL-60 cells with PD98059 (PD) pretreatment. (C) RC-RNase induces cytotoxicity on undiﬀerentiated HL-60
cells with bisindolylmaleimide I (BI) pretreatment. Each data point was calculated from four triplicate groups and displayed as means ± S.D.
Fig. 3. TPA-diﬀerentiated cells inhibit RC-RNase-induced cytotoxicity through PKC and MEK pathways. (A) RC-RNase can not induce
cytotoxicity on TPA-diﬀerentiated HL-60 cells. (B) RC-RNase induces cytotoxicity on TPA-diﬀerentiated HL-60 cells with PD98059 (PD)
pretreatment. (C) RC-RNase induces cytotoxicity on TPA-diﬀerentiated cells HL-60 with bisindolylmaleimide I (BI) pretreatment. Each data point
was calculated from four triplicate groups and displayed as means ± S.D.
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contrast, the cell numbers in TPA-diﬀerentiated cells with bis-
indolylmaleimide I or PD98059 pretreatment decreased signif-
icantly (Fig. 3B and C). Furthermore, RC-RNase decreased
the cell number in undiﬀerentiated cells following bisindolyl-
maleimide I or PD98059 pretreatment (Fig. 2B and C). Sum-
marised, our data shows that TPA-diﬀerentiated cells inhibit
RC-RNase-induced cytotoxicity through the PKC and MEK
pathways.
3.3. Caspase-9/-3 activation is inhibited on TPA-diﬀerentiated
cells
After RC-RNase treatment, caspase-9/-3 activities are in-
duced in undiﬀerentiated cells but are inhibited in TPA-diﬀer-
entiated cells (Fig. 4). In addition, RC-RNase does not inhibit
caspase-9/-3 activities on TPA-diﬀerentiated cells pretreated
with bisindolylmaleimide I or PD98059 (Fig. 4). Our study
also showed that if undiﬀerentiated cells were pretreated with
bisindolylmaleimide I or PD98059, then RC-RNase can not in-
hibit caspase-9/-3 activities on these cells (Fig. 4).
3.4. Caspase-9/-3 activation is inhibited on RA-diﬀerentiated
cells
Undiﬀerentiated cells and RA-diﬀerentiated cells can be eas-
ily determined by a NBT assay. RA-diﬀerentiated cells can re-
duce NBT and generate the black–blue formazan product. In
this study, undiﬀerentiated HL-60 cells (Fig. 5A) were success-
fully induced to diﬀerentiate into granulocytes with retinoic
acid treatment (RA-diﬀerentiated cells) (Fig. 5B). The diﬀeren-tiation procedure was only inhibited if these cells were treated
with bisindolylmaleimide I or PD98059 (Fig. 5C and D). Like
TPA-diﬀerentiated cells, RA-diﬀerentiated cells can inhibit
RC-RNase-induced caspase-9/-3-mediated cytotoxicity and
cannot inhibit RC-RNase-induced caspase-9/-3-mediated cyto-
toxicity after pretreatment with PD98059 or bisindolylmaleim-
ide I pretreatment (Fig. 6). Overall, our study shows that PKC
and MEK pathways inhibit RC-RNase-induced caspase-9/-3-
mediated cytotoxicity on TPA- and RA-diﬀerentiated cells.4. Discussion
Previous studies showed that RC-RNase induce a strong
cytotoxicity on poorly diﬀerentiated hepatoma cells but not
on well-diﬀerentiated hepatoma cells [4]. Moreover, it has been
demonstrated that RC-RNase induced cytotoxicity on undif-
ferentiated cells but not on RA-diﬀerentiated cells [5]. Pres-
ently, this study demonstrates that TPA-diﬀerentiated cells
can also inhibit RC-RNase-induced cytotoxicity (Fig. 3).
These studies indicate that RC-RNase-induced cytotoxicity
correlates with cell diﬀerentiation though the mechanisms re-
main unclear.
HL-60 cells can be induced to diﬀerentiate into granulocytes
or into macrophage-like cells after pretreatment with RA and
TPA, respectively [9,10]. This study also showed that PKC and
MEK pathways could be activated on TPA- and RA-diﬀeren-
tiated cells [10–12,18–21]. Therefore, we consider that diﬀeren-
tiated cells inhibit RC-RNase-induced cytotoxicity through
Fig. 4. PKC and MEK pathways inhibit RC-RNase-induced caspase-
9/-3-mediated cytotoxicity on TPA-diﬀerentiated cells. (A) Caspase-9
and (B) caspase-3 activities are determined on diﬀerent HL-60 cells
with RC-RNase treatment for 72 h. Fold increase of caspases activities
are determined as described in Section 2.6. Note cells used in the study
are undiﬀerentiated cells (C), TPA-diﬀerentiated cells (TPA), TPA-
diﬀerentiated cells with PD98059 (TPA + PD) or bisindolylmaleimide I
(TPA + BI) pretreatment and undiﬀerentiated cells with PD98059
(C + PD) or bisindolylmaleimide I (TPA + BI) pretreatment. Only
TPA-diﬀerentiated cells inhibit RC-RNase-induced caspases activa-
tion. Each data point was calculated from four triplicate groups and
displayed as means ± S.D.
Fig. 6. PKC and MEK pathways inhibit RC-RNase-induced caspase-
9/-3-mediated cytotoxicity on RA-diﬀerentiated cells. (A) Caspase-9
and (B) caspase-3 activities are determined on diﬀerent HL-60 cells
with RC-RNase treatment for 72 hours. Note: Cells used in the study
are undiﬀerentiated cells (C), RA-diﬀerentiated cells (RA), RA-
diﬀerentiated cells with PD98059 (RA + PD) or bisindolylmaleimide
I (RA + BI) pretreatment and undiﬀerentiated cells with PD98059
(C + PD) or bisindolylmaleimide I (TPA + BI) pretreatment. Only
RA-diﬀerentiated cells inhibit RC-RNase-induced caspases activation.
Each data point was calculated from four triplicate groups and
displayed as means ± S.D.
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PKC and MEK inhibitors were used to block these pathways,
which make the cells unable to inhibit RC-RNase-induced
cytotoxicity. Our obtained data suggests that the PKC and
MEK pathways can inhibit RC-RNase-induced cytotoxicity.
Previous studies showed that the p38 pathway is related to
HL-60 cells diﬀerentiation [12]. To test whether the p38 path-
way inhibits RC-RNase-induced cytotoxicity, a p38 inhibitor
(SB202190) was used in this study. Results showed that
RC-RNase cannot induce cytotoxicity on diﬀerentiated cellsFig. 5. RA-diﬀerentiated cells can reduce NBT and generate blue–black form
diﬀerentiate into granulocytes with RA treatment for 5 days (RA-diﬀerent
treatment (PD + RA). (D) HL-60 cells are pretreated with bisindolylmaleimid
can reduce NBT to generate blue–black formazan.despite pretreatment with p38 inhibitor (data not shown).
Thus, the p38 pathway cannot inhibit RC-RNase-induced
cytotoxicity. Taken together, our study is the ﬁrst to demon-
strate that RC-RNase-induced cytotoxicity is inhibited
through the PKC and MEK pathways but not through the
p38 pathway.
Two major caspase-mediated cytotoxicity pathways have
been described in previous studies. The death receptor path-
way, in which caspase-8 is activated through cell surface recep-
tors [22] and the mitochondrial death pathway, in which
caspase-9 is activated through mitochondrial alterations [23].
It has been demonstrated before that the MEK pathway canazan. (A) Undiﬀerentiated HL-60 cells. (B) HL-60 cells are induced to
iated cells). (C) HL-60 cells are pretreated with PD98059 before RA
e I before RA treatment (BI + RA). Note: Only RA-diﬀerentiated cells
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MEK pathway can inhibit caspase-9/-3 activation remains un-
clear. Our study is able to demonstrate that RC-RNase can not
induce caspase-9/-3 activation on diﬀerentiated cells, but if the
diﬀerentiated cells are pretreated with MEK inhibitor, RC-
RNase is able to induce caspase-9/-3 activation (Fig. 4). The
data indicate that the MEK pathway inhibits not only cas-
pase-8 activation but also caspase-9/-3 activation. The data ob-
served from this study further identiﬁed that RC-RNase can
not induce caspase-9/-3 activation on diﬀerentiated cells unless
the cells were pretreated with PKC inhibitor. In summary, our
study is the ﬁrst to indicate that both MEK and PCK path-
ways can inhibit caspase-9/-3 activation.Acknowledgement: This work was sponsored by a Grant from the Na-
tional Science Council, ROC (NSC 95-2320-B-241-007) and Tzu-Chi
hospital (TCRD96-13 and TCRD-97-06).Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.febs-
let.2008.02.018.
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